Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2002;4(4):E27.
doi: 10.1208/ps040427.

Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis

Affiliations
Comparative Study

Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis

Ulrika Wählby et al. AAPS PharmSci. 2002.

Abstract

The aim of this study was to compare 2 stepwise covariate model-building strategies, frequently used in the analysis of pharmacokinetic-pharmacodynamic (PK-PD) data using nonlinear mixed-effects models, with respect to included covariates and predictive performance. In addition, the effects of stepwise regression on the estimated covariate coefficients were assessed. Using simulated and real PK data, covariate models were built applying (1) stepwise generalized additive models (GAM) for identifying potential covariates, followed by backward elimination in the computer program NONMEM, and (2) stepwise forward inclusion and backward elimination in NONMEM. Different versions of these procedures were tried (eg, treating different study occasions as separate individuals in the GAM, or fixing a part of the parameters when the NONMEM procedure was used). The final covariate models were compared, including their ability to predict a separate data set or their performance in cross-validation. The bias in the estimated coefficients (selection bias) was assessed. The model-building procedures performed similarly in the data sets explored. No major differences in the resulting covariate models were seen, and the predictive performances overlapped. Therefore, the choice of model-building procedure in these examples could be based on other aspects such as analyst- and computer-time efficiency. There was a tendency to selection bias in the estimates, although this was small relative to the overall variability in the estimates. The predictive performances of the stepwise models were also reasonably good. Thus, selection bias seems to be a minor problem in this typical PK covariate analysis.

PubMed Disclaimer

References

    1. Beal SL, Sheiner LB. NONMEM Users Guides. San Francisco, CA: University of California; 1992.
    1. Maitre PO, Buhrer M, Thomson D, Stanski DR. A three-step approach combining Bayesian regression and NONMEM population analysis: application to midazolam. J Pharmacokinet Biopharm. 1991;19(4):377–384. doi: 10.1007/BF01061662. - DOI - PubMed
    1. Mandema JW, Verotta D, Sheiner LB. Building population pharmacokinetic-pharmacodynamic models. I. Models for covariate effects. J Pharmacokin Biopharm. 1992;20(5):511–528. doi: 10.1007/BF01061469. - DOI - PubMed
    1. Gallo JM, Laub PB, Rowinsky EK, Grochow LB, Baker SD. Population pharmacokinetic model for topotecan derived from phase I clinical trials. J Clin Oncol. 2000;18(12):2459–2467. - PubMed
    1. Troconiz IF, Armenteros S, Planelles MV, Benitez J, Calvo R, Dominguez R. Pharmacokinetic-Pharmacodynamic Modelling of the antipyretic effect of two oral formulations of ibuprofen. Clin Pharmacokinet. 2000;38(6):505–518. doi: 10.2165/00003088-200038060-00004. - DOI - PubMed

Publication types

LinkOut - more resources